Genencor International (NASDAQ:GCOR)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Genencor International Charts. Click Here for more Genencor International Charts.](/p.php?pid=staticchart&s=N%5EGCOR&p=8&t=15)
Genencor/NREL Team Wins R&D Top 100 Award for Work Enabling the
Conversion of Biomass to Ethanol
R&D Magazine's List of Most Technological Significant Products
PALO ALTO, Calif., July 14 /PRNewswire-FirstCall/ -- Genencor International,
Inc. (NASDAQ:GCOR), and a team from the U.S. Department of Energy's National
Renewable Energy Laboratory (NREL) have been selected by R&D Magazine for its
list of the Top 100 Technologically Significant Products for 2004. The
organizations were cited for their progress toward an economical process for
converting biomass to ethanol. The award is shared with Novozymes Biotech, Inc.
According to NREL, the technology is expected to allow a wide range of biomass
resources to be used to produce energy and chemicals. It is an important step
toward realizing the potential of biorefineries -- in which plant and waste
materials are used to produce an array of fuels and chemicals, analogous to an
oil refinery today. Through this technology, the cost of converting cellulosic
biomass into usable sugars can be reduced by more than 20 times per gallon of
ethanol produced.
"We're extremely pleased to receive this recognition and continue to work
toward making biorefineries a reality," said Bill Dean, Genencor vice president
of Development.
The complete list of award winners will be revealed in the September issue of
R&D Magazine.
About Genencor
Genencor International is a diversified biotechnology company that develops and
delivers innovative products and services into the health care,
agri-processing, industrial and consumer markets. Using an integrated set of
technology platforms, Genencor's products deliver innovative and sustainable
solutions to improve the quality of life. Genencor traces its history to 1982
and has grown to become a leading biotechnology company, with over $380 million
in year 2003 annual revenues. Genencor has principal offices in Palo Alto,
California; Rochester, New York; and Leiden, the Netherlands.
This press release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995. These include statements
concerning plans, objectives, goals, strategies, future events or performance
and all other statements which are other than statements of historical fact,
including without limitation, statements containing words such as "believes,"
"anticipates," "expects," "estimates," "projects," "will," "may," "might" and
words of a similar nature. Such statements involve risks and uncertainties that
could cause actual results to differ materially from those projected. Some
important factors that could cause actual results to differ include dependence
on the efforts of third parties; dependence on new and uncertain technology and
its uncertain application to new business ventures; regulatory actions or
delays, or uncertainties related to product development, testing or
manufacturing; ability to form and maintain strategic alliances; dependence on
certain intellectual property rights of both Genencor and third parties; and
the competitive nature of Genencor's industry; risks of obsolescence of certain
technology. These and other risk factors are more fully discussed in Genencor's
most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed
with the United States Securities and Exchange Commission. The forward-looking
statements contained in this release represent the judgment of Genencor as of
the date of this press release. Genencor disclaims, however, any intent or
obligation to update any forward-looking statements.
DATASOURCE: Genencor International, Inc.
CONTACT: Valerie Tucker of Genencor International, Inc.,
+1-650-846-7571
Web site: http://www.genencor.com/